

**To Print: Click your browser's PRINT button.**

**NOTE:** To view the article with Web enhancements, go to:

<http://www.medscape.com/medline/abstract>

---

## **Probing for nasolacrimal duct obstruction using intranasal midazolam sedation as an alternative to general anesthesia.**

**J Pediatr Ophthalmol Strabismus. 2006; 43(2):79-84; quiz 100-1 (ISSN: 0191-3913)**

---

Karabas LV ; Elibol O ; Yüksel N ; Gürkan Y ; Altintas O ; Caglar Y  
Ophthalmology Department, Kocaeli University School of Medicine, Turkey.

**OBJECTIVE:** To investigate the effectiveness of topical anesthesia with sedation using intranasal midazolam in patients with symptomatic congenital nasolacrimal duct obstruction undergoing probing. **PATIENTS AND METHODS:** In this prospective study, probing was performed with general anesthesia (30 cases) and with topical anesthesia using intranasal midazolam (0.3 mg/kg; 44 cases) in 74 patients who were divided into two groups, those 6 to 36 months old and those older than 36 months. The groups were compared after 12 to 48 months (mean, 18.2 months). **RESULTS:** For the patients 6 to 36 months old, the success rate was 80% in the group who received general anesthesia and 88.9% in the group who received topical anesthesia with intranasal midazolam; the difference between the two groups was not statistically significant ( $P > .05$ ). For the patients older than 36 months, the success rate was 20% in the group who received general anesthesia and 25% in the group who received topical anesthesia with intranasal midazolam; there was no statistically significant difference between the two groups ( $P > .05$ ). **CONCLUSIONS:** Probing with topical anesthesia in the office setting is usually recommended for patients younger than 8 months. Our results show that this is suitable for children until 4 years of age with the support of intranasal midazolam sedation. Probing under topical anesthesia with intranasal midazolam is cost-effective, safe, and comparable in efficacy to probing under general anesthesia but with less risk.

PreMedline Identifier: 16598973

---